lems are more likely to occur in patients with underlying breathing problems, elderly patients, or impaired or weak patients. These problems usually occur after large initial doses in patients who are not opioid tolerant or when opioids are given with other medicines that that slow breathing.
ABSTRAL is made with the prescription medicine fentanyl. Your healthcare provider will prescribe a starting dose of ABSTRAL that may be different than other fentanyl-containing medicines you may have been taking. Do not switch from ABSTRAL to other medicines that contain fentanyl without talking with your healthcare provider.
ABSTRAL is a federally controlled substance (CII) because it is a strong opioid (narcotic) pain medicine that can be misused by people who abuse prescription medicines or street drugs.
Never give ABSTRAL to anyone else, even if they have the same symptoms you have. It may harm them or cause death.
Do not take ABSTRAL for short-term pain that you would expect to go away in a few days, such as pain after surgery, headache, migraine, or dental pain.
Do not take ABSTRAL if you are allergic to any of the ingredients in ABSTRAL.
Tell your doctor about all of your medical and mental health problems. If you have trouble breathing or lung problems such as asthma, wheezing, or shortness of breath, ABSTRAL may cause more serious breathing problems.
Do not take any medicine while using ABSTRAL until you have talked to your healthcare provider. Be very careful about taking other medicines that may make you sleepy, such as other pain medicines, anti-depressants, sleeping pills, anti-anxiety medicines, antihistamines, or tranquilizers. Also, do not drink alcohol while using ABSTRAL.
Do not drive, operate heavy machinery, or do other dangerous activities until you know how ABSTRAL affects you. ABSTRAL can make you sleepy. Ask your healthcare provider when it is ok
'/>"/>
SOURCE ProStrakan, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related medicine technology :1.
FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women2.
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV3.
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder4.
European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection5.
FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults6.
FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria7.
UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies8.
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)9.
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older10.
FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer11.
EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435